Nuvation Bio shares pivotal China data for cancer drug from AnHeart buyout

Nuvation Bio showcased longer-term Phase 2 data around the next-gen ROS1 inhibitor it hopes will give Pfizer and Bristol Myers Squibb a run for their money.

In a study conducted in China, taletrectinib spurred an overall response rate of 91% among advanced and metastatic non-small cell lung cancer patients with the ROS1 mutation who have never taken a tyrosine kinase inhibitor (TKI), out to a median follow-up of 23.5 months. In a smaller group of patients pretreated with a TKI, the overall response rate was 52% at a median follow-up of 9.7 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

More Than 1 in 4 Seniors Have Asymptomatic Valve Disease

Undiagnosed heart valve disease was highly prevalent in a large community study of otherwise healthy people recruited from primary care in the U.K., researchers found.

June 28, 2024

Clinical Challenges: Integrating Diet Into Crohn’s Disease Management

Incorporating diet into Crohn’s disease (CD) treatment regimens has some support, with a shift toward a whole-foods nutrition approach for symptom relief and healing. Although

December 28, 2023

NVIDIA Makes Drug Discovery, Medical Imaging, and Genomics Easier with Cloud-Based AI

What You Should Know: – Harnessing the power of AI for healthcare just got simpler. NVIDIA announced the integration of NVIDIA NIM, a collection of

May 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.